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Treatment with mRNA coding for the necroptosis
mediator MLKL induces antitumor immunity
directed against neo-epitopes
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Cancer immunotherapy can induce durable antitumor responses. However, many patients
poorly respond to such therapies. Here we describe a generic antitumor therapy that is based
on the intratumor delivery of mRNA that codes for the necroptosis executioner mixed lineage
kinase domain-like (MLKL) protein. This intervention stalls primary tumor growth and pro-
tects against distal and disseminated tumor formation in syngeneic mouse melanoma and
colon carcinoma models. Moreover, MLKL-mRNA treatment combined with immune
checkpoint blockade further improves the antitumor activity. MLKL-mRNA treatment rapidly
induces T cell responses directed against tumor neo-antigens and requires CD4+ and CD8+
T cells to prevent tumor growth. Type I interferon signaling and Batf3-dependent dendritic
cells are essential for this mRNA treatment to elicit tumor antigen-speciﬁc T cell responses.
Moreover, MLKL-mRNA treatment blunts the growth of human lymphoma in mice with a
reconstituted human adaptive immune system. MLKL-based treatment can thus be exploited
as an effective antitumor immunotherapy.
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Cancer cells evade the immune system in many ways. Theclinical success of immunotherapies that are based on the(re-)activation of antitumor T cells has revolutionized
cancer treatment and highlights the tremendous power of T cells
to control malignant diseases1–3. Nonetheless, the majority of
patients remain unresponsive to the current immunotherapies
that are based on so called checkpoint inhibitors4–6. A growing
body of evidence indicates that checkpoint inhibitor unrespon-
siveness correlates with a lack of CD8+ T cells inside the
tumor6,7. The extent of T cell inﬁltration into tumors in turn
depends on prior innate immune activation in the tumor
microenvironment (TME) and the recruitment of Batf3-
dependent CD103+ dendritic cells (DCs)8. These Batf3-
dependent DCs are not only required for the initial priming of
antitumor T cell responses in the tumor draining lymph nodes
but also secrete the appropriate chemokines to attract effector
T cells8. Defective T cell priming could potentially be overcome
by active vaccination strategies directed against tumor antigens or
by adoptive T cell therapies. However, immunologically quiescent
tumors can resist such strategies because T cells fail to migrate
into the tumor bed8.
An immunogenic tumor environment can be created by eli-
citing immunogenic cell death, which represents a common
denominator for a variety of cell death pathways that result in the
release of damage-associated molecular patterns (DAMPs) and
other immune-stimulatory components that can recruit and
activate DCs in the TME9–11. For example, immunogenic apop-
tosis of neoplastic cells has been documented in response to
irradiation, chemotherapeutics, and hypericin-based photo-
dynamic therapy12–16. In addition to certain apoptosis modalities,
necroptosis has been identiﬁed as a type of cell death with
immunogenic properties17,18. Necroptosis can be induced by
activation of death receptors, Toll-like receptors, intracellular
RNA and DNA sensors, and by some chemical drugs19. The core
necroptotic pathway involves phosphorylation of receptor inter-
acting protein kinase 3 (RIPK3), which subsequently phosphor-
ylates mixed lineage kinase domain-like protein (MLKL)20–25.
Phosphorylated MLKL oligomerizes and subsequently translo-
cates to the plasma membrane where it inﬂicts membrane per-
meabilization and necroptosis23–28. Strikingly, genetic and
epigenetic changes in the pathways that lead to necroptosis have
been described for many tumor types. Strongly reduced RIPK3
expression levels, the kinase that phosphorylates and thereby
activates MLKL, for example, have been documented in colon
carcinoma and are frequent in acute myeloid and chronic lym-
phocytic leukemia29. Moreover, in pancreatic cancers, reduced
MLKL expression is associated with decreased survival30,31.
We hypothesized that genetic delivery of MLKL into the TME
could create an immunogenic environment that subsequently
instills adaptive antitumor immunity. For this delivery, we opted
to apply in vitro transcribed mRNA as a way to express MLKL in
the TME because mRNA has emerged as an extremely versatile
platform to deliver genetically encoded therapeutics in situ32,33.
We demonstrate that intratumor administration of mRNA
encoding MLKL elicits a potent antitumor T cell response—
involving T cells directed against tumor neo-antigens—even in
tumors that are defective for upstream necroptotic signaling
proteins. MLKL-mRNA treatment protected in two syngeneic
mouse tumor models and even in mice with a humanized
immune system that had been inoculated with human lymphoma
cells.
Results
MLKL mRNA induces necroptosis-like tumor cell death. In
vitro transcribed mRNA has been widely explored to deliver
directly translatable coding information in in vitro cultured cells,
in experimental animal models, and in patients34,35. We therefore
generated hypo-inﬂammatory mRNAs (Supplementary Fig. 1a-b)
to assess the potential antitumor outcome of transiently expressed
MLKL and, in comparison, truncated Bcl2-like inducer of cell
death (tBid). MLKL is crucial for the execution of necroptosis,
while tBid, the caspase-cleaved form of Bid, is an inducer of
intrinsic apoptotic cell death22,36. First, we assessed the kinetics of
mRNA uptake and translation. Fluorescently labeled green
ﬂuorescent protein (GFP)-mRNA was rapidly detectable in
transfected B16 melanoma cells and the expression of the enco-
ded GFP became visible 8 h after transfection (Supplementary
Fig. 1c). In vivo, similar expression kinetics were found: intra-
tumor delivery of mRNA resulted in a peak of expression of the
encoded ﬁreﬂy luciferase (Fluc) reporter at 12 h after electro-
poration of injected mRNA (Supplementary Fig. 1d).
We next analyzed the extent and mode of cell death of B16
melanoma cells after transfection with mRNA encoding MLKL or
tBid. Transfection of B16 cells with tBid-mRNA elicited hall-
marks of apoptotic cell death: caspase activity was induced and
typical cleavage fragments of caspase-3 were observed, cell death
was prevented by the pan-caspase inhibitor zVAD-fmk, and
ﬁnally cells became sytox positive due to loss of plasma
membrane integrity following secondary necrosis (Fig. 1a–c and
Supplementary Fig. 2). In contrast, cell death following MLKL-
mRNA transfection proceeded without caspase activity or
caspase-3 processing, the cells became sytox positive, but in
contrast to apoptosis the addition of zVAD-fmk did not prevent
cell death, all of which are features of necroptosis (Fig. 1a–c and
Supplementary Fig. 2). Cell death induced by mRNA encoding
tBid or MLKL did not activate nuclear factor (NF)-κB signaling in
the B16 melanoma cells (Fig. 1d). Moreover, the extent of cell
death following tBid or MLKL mRNA transfection was compar-
able in the presence or absence of actinomycin D, suggesting that
de novo transcription was not required (Fig. 1e). Time-lapse
microscopy conﬁrmed that tBid-mRNA transfection of B16
melanoma cells induced apoptotic membrane blebbing, whereas
MLKL-mRNA transfection resulted in cell rounding, followed by
swelling and eventually plasma membrane permeabilization
(Fig. 1f and supplementary movies 1 and 2)37. Finally, to assess
the extent of cell death in vivo, B16 melanoma cells were injected
subcutaneously (s.c.) into the ﬂank of C57Bl/6 mice, and 6 days
later, MLKL- and tBid-mRNA was administered into the tumor
(mRNA injection followed by electroporation). Flow cytometric
analysis of tumor cells isolated 24 h after in vivo mRNA
electroporation revealed that MLKL- and tBid-mRNA electro-
poration resulted in a very similar level of cell death, which was
approximately three-fold higher than the extent of tumor cell
death in the saline and irrelevant control mRNA settings (Fig. 1g).
Intratumor delivery of MLKL-mRNA stalls tumor growth. We
next evaluated the impact on tumor growth of intratumor
delivery of mRNA encoding tBid or MLKL in syngeneic B16
(melanoma)38 and CT26 (colon carcinoma)39 tumor models.
C57BL/6 mice were s.c. inoculated with B16-ovalbumin (B16-
OVA) melanoma cells. Established tumors were then treated with
saline or mRNAs encoding Fluc (as negative control), tBid, or
MLKL according to the schedule shown in Fig. 2a. The tumor
growth rate following saline injection and Fluc-mRNA injection
followed by electroporation was identical, indicating that mRNA
electroporation by itself does not induce adequate immune acti-
vation (Fig. 2b and Supplementary Fig. 3). In contrast, intratumor
treatment with tBid-mRNA delayed tumor growth and increased
the median survival time (time point at which the ethical end
point was reached) of the mice from 23 to 43 days (Fig. 2b
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and Supplementary Fig. 3). However, the most striking antitumor
effect was observed for intratumor treatment with MLKL-mRNA:
this treatment signiﬁcantly delayed tumor growth and increased
the median survival time to 64 days (Fig. 2b and Supplementary
Fig. 3). Since, as noted above, tBid- and MLKL-mRNA treatment
induced very similar levels of tumor cell death, we can also
conclude that the mere induction of cell death is not sufﬁcient to
induce a strong antitumor response.
Genetic and epigenetic alterations in the pathways that lead to
necroptosis are common in cancer cells29. Although CT26 tumor
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cells do not express RIPK318, the therapeutic effect of MLKL-
mRNA treatment resulted in a very pronounced antitumor effect,
increasing the median survival time to >60 days and 60% of the
treated mice even remained tumor free up to 80 days after CT26
inoculation (Fig. 2c and Supplementary Fig. 3). Presumably, and
in line with a recent report40, the level of MLKL expression that is
reached after mRNA electroporation of CT26 cells is sufﬁciently
high to elicit cell death in the absence of RIPK3.
Some of the standard-of-care therapies for cancer patients can
induce immunogenic cell death, such as treatment with
doxorubicin (dox)12. We compared the antitumor effect of the
MLKL-mRNA treatment approach with repeated injections of
dox in the B16 melanoma model (Fig. 3a). Dox injections were
administered every other day into the tumor or intraperitoneally
for 3 weeks. Mice from another group were treated on days 6, 8,
and 10 only by intratumor injection of dox. MLKL-mRNA
treatment was associated with signiﬁcantly prolonged survival of
the mice compared with any of the dox treatment set-ups (Fig. 3b,
c and Supplementary Fig. 3). In addition, the prolonged treatment
with dox during 3 weeks was associated with signiﬁcantly reduced
body weight compared with the MLKL-mRNA-treated group and
with lymphocytopenia (Fig. 3d, e).
MLKL-mRNA treatment induces systemic antitumor respon-
ses. We hypothesized that the induction of cell death in the tumor
by mRNA encoding MLKL could promote the induction of
antitumor T cell responses through the release of tumor antigens
alongside DAMP12,41. Such tumor-speciﬁc T cell responses can in
principle also obstruct the growth of non-treated distal tumors
and metastases. To address whether local intratumor mRNA
treatment could induce such an immune-related abscopal effect,
we surgically removed the primary tumor 2 days after the second
treatment and challenged the mice 2 days later by s.c. injection of
B16 or CT26 cells in the opposite ﬂank (Fig. 4a). Intratumor
treatment of primary tumors with saline or control mRNA
resulted in comparable secondary tumor growth (Fig. 4b, c and
Supplementary Fig. 3). tBid-mRNA treatment of the primary
tumor provided a modest protection against tumor rechallenge
(Fig. 4b, c and Supplementary Fig. 3). However, intratumor
treatment of primary tumors with MLKL-mRNA induced a
robust protection against tumor rechallenge with 40% of the B16
inoculated mice being tumor free by day 86 and all of the CT26
inoculated mice remaining tumor free up to day 60 of the
experiment (Fig. 4b, c and Supplementary Fig. 3).
We also tested the systemic immunity in a second model where
a possible abscopal effect could be evaluated42. Mice were
inoculated with B16 cells in either ﬂank but on different days: the
tumor in the left ﬂank was implanted 3 days later than the tumor
in the right ﬂank. Only the tumor in the right ﬂank of the animals
was subsequently treated, starting at day 6 after the ﬁrst
inoculation. The growth of the distant untreated tumor in the
left ﬂank was monitored over time (Fig. 4d). Also, in this set-up, a
pronounced delay in tumor growth of the untreated tumor was
observed in the case of MLKL-mRNA treatment (Fig. 4d and
Supplementary Fig. 3).
Finally, we also evaluated the protective potential of intratumor
mRNA delivery in a lung colonization assay. Primary tumors
were removed 2 days after the second treatment and mice were
subsequently challenged by intravenous (i.v.) injection of B16-F10
or CT26 cells (Fig. 5a). In saline as well as in control mRNA-
treated mice, this resulted in the rapid development of tumor
nodules in the lungs (Fig. 5b, c). In contrast, intratumor
treatment with mRNA coding for MLKL completely protected
against lung tumor nodule formation in both the B16 and CT26
models, whereas tBid-mRNA induced only partial protection
(Fig. 5b, c).
In summary, intratumor delivery of mRNA encoding MLKL
elicits a strong and systemic antitumor immune response that
reduces growth not only of the treated tumor but also can prevent
secondary local and experimentally disseminated tumor
formation.
MLKL-mRNA combined with anti-PD1 improves antitumor
cure. The antitumor activity of MLKL-mRNA treatment might be
further improved when combined with cancer treatment options
that are already clinically established such as checkpoint blockade
approaches. Once inside the tumor bed, T cells primed by
intratumor MLKL-mRNA treatment might be silenced by mul-
tiple immune-suppressive mechanisms used by tumors to evade
elimination43. Checkpoint inhibitors such as anti-CTLA4, -PD1,
and -PD-L1, indoleamine 2,3-dioxygenase inhibitors or reg-
ulatory T depletion strategies primarily act by taking away these
breaks. However, these treatments are unfortunately poorly
effective in patients with tumors with a low number of tumor-
inﬁltrating T cells6. Since the MLKL-based mRNA therapy
reported here induces robust inﬁltration of antigen-presenting
cells into the tumor, it is possible that a combination therapy with
a checkpoint inhibitor could further improve the curative
potential of intratumor delivery of MLKL-mRNA. B16 tumors
were implanted s.c. in the right ﬂank of the mice and, 3 days later,
in the left ﬂank of the mice. On day 6, the tumor that was
inoculated ﬁrst was treated with MLKL mRNA in combination
with i.p. administration of anti-PD1 or an isotype control anti-
body (Fig. 6a). The anti-PD1 combination therapy was sig-
niﬁcantly more effective at suppressing the growth of the primary
treated tumor and of the distant untreated tumor than the
MLKL-mRNA treatment combined with the control antibody
(Fig. 6b, c and Supplementary Fig. 3).
Fig. 1MLKL encoding mRNA induces cell death in vitro and in vivo. a–f In vitro cell death characterization. B16-OVA cells were transfected with PBS or with
Fluc-, tBid-, or MLKL-mRNA. a At different time points after transfection, cells were collected and analyzed by ﬂow cytometry. Graph showing the
percentages of sytox+ cells (left). Representative ﬂow cytometric plots 24 h after transfection (right). b Impact of the pan-caspase inhibitor zVAD-fmk on
cell death induction (top) and caspase activity (bottom) upon transfection of B16-OVA cells with tBID- or MLKL-mRNA. c Western blot analysis of the
expression of MLKL, caspase-3, and cleaved caspase-3 in cell lysates prepared 24 h after mRNA transfection. Tubulin served as a loading control. d B16
cells were co-transfected with luciferase NF-κB reporter plasmid and a plasmid expressing β-galactosidase. Twenty four hours later, the cells were
transfected with PBS, GFP-, tBid-, or MLKL-mRNA or, as a positive control for NF-κB activation, with TRAF6 expression vector or they were stimulated with
TNF. The normalized luciferase activity in the lysates determined at different time points after mRNA transfection is depicted. e B16 cells were transfected
with a GFP expression plasmid. Twenty four hours later, the cells were transfected with PBS, Fluc-, tBid-, or MLKL-mRNA and the cells were treated or not
with actinomycin D as indicated. Twenty four hours after mRNA transfection, cell death and GFP expression were quantiﬁed using ﬂow cytometry.
Horizontal lines indicate the mean. f Still images of B16-OVA cells at 0 and 24 h after transfection with tBid- or MLKL-mRNA visualized by time-lapse
microscopy (scale bar= 10 µm). g In vivo cell death characterization. Subcutaneously growing B16-OVA tumors were injected with PBS or with 10 µg
mRNA encoding Fluc, tBid, or MLKL followed by electroporation. Twenty four hours later, the tumor cells were isolated and analyzed by ﬂow cytometry for
sytox uptake. Graph showing the percentages of sytox+ cells (left) and representative ﬂow cytometry plots (right). Horizontal lines indicate the mean
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MLKL-mRNA induces protective tumor epitope-speciﬁc
T cells. To address the capacity of intratumor MLKL-mRNA
treatment to prime antitumor T cells, we adoptively transferred
carboxyﬂuorescein diacetate succinimidyl ester (CFSE)-labeled
OVA-speciﬁc transgenic CD8+ (OT-I) or CD4+ T cells (OT-II)
into B16-OVA bearing mice 2 days prior to intratumor mRNA
treatment. The tumor draining lymph nodes were excised and T
cell proliferation was assessed by ﬂow cytometry 2 days after a
single mRNA treatment (Supplementary Fig. 4: gating strategy).
We found that only intratumor MLKL-mRNA treatment resulted
in signiﬁcant OT-I and OT-II proliferation compared to control
treatment (Fig. 7a). Likewise, only MLKL-mRNA treatment
resulted in signiﬁcant numbers of interferon-γ (IFN-γ) producing
OVA-peptide-speciﬁc CD4+ and CD8+ T cells in the tumor
draining lymph node (Fig. 7b). The capacity of the primed CD8+
T cells to recognize and kill target cells was next evaluated by an
in vivo killing assay. Intratumor treatment with MLKL-mRNA
was associated with up to 75% speciﬁc killing of target cells
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compared to 40% in mice that had been treated with mRNA
encoding tBid, whereas intratumor administration of Fluc-mRNA
did not instigate signiﬁcant target cell lysis (Fig. 7c; Supplemen-
tary Fig. 5).
The data above show that the antitumor response induced by
intratumor treatment with mRNA encoding MLKL can lead to
priming of tumor xeno-antigen-speciﬁc CD8+ and CD4+ T cells
and to the elimination of cells that display this antigen. We also
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found that deletion of CD8+ T cells completely and of CD4+
T cells partially abolished the antitumor effect evoked by the
intratumor treatment with mRNA encoding MLKL (Fig. 7d).
These results indicate that CD8+ and, to a lesser extent, CD4+
T cells contribute for the therapeutic antitumor effect of MLKL-
mRNA.
Successful induction of neo-epitope-speciﬁc T cell responses is
associated with improved therapeutic outcomes in cancer
Fig. 4MLKL-mRNA protects against tumor rechallenge and distal tumors. a Schematic representation of the treatment and rechallenge experiment. b B16-
OVA cells or c CT26-OVA cells were s.c. inoculated in the right ﬂank of C57BL/6J or BALB/cAnNCrl mice (n= 5 per group), respectively. On days 6 and
10 (treatments 1 and 2, respectively), the tumors were injected with saline or 10 µg mRNA encoding Fluc, tBid, or MLKL followed by electroporation. After
intratumor treatment, the primary tumor was removed on day 12, and 2 days later, a second inoculation of B16 or CT26 cells in the opposite ﬂank of the
mice was performed. Mice were euthanized when tumors reached 1000mm3 in size. The lower graph panels in b, c depict the percentage of survival (left)
and tumor-free mice (right). The results shown in b are representative for three independent repeats. Cox regression analyses showed that there was no
difference between the repeat experiments. *p < 0.0.5; **p < 0.01 (log-rank test of Kaplan–Meier curves). d B16-cells were s.c. inoculated in the right and on
day 3 in the left ﬂank of C57BL/6J mice. On days 6 and 10, the tumors on the right ﬂank were injected with saline or 10 µg mRNA encoding Fluc, tBid, or
MLKL followed by electroporation. The growth of the untreated tumor that had been inoculated in the left ﬂank was measured over time. Mice were
euthanized when the tumor of the right ﬂank had reached a volume of 1000mm3. The experiment was performed once with 5 mice per group in the PBS
and luciferase mRNA set-up and 8 mice per group in the tBid- and MLKL-mRNA treatment groups
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Fig. 5 Intratumor MLKL-mRNA protects against experimental lung colonization. a Schematic representation of the experiment. B16-OVA (b) or CT26-OVA
cells (c) were s.c. inoculated in the ﬂank of C57BL/6J or BALB/cAnNCrl mice, respectively. After intratumor mRNA treatments 1 and 2 and primary tumor
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group, and from one experiment for the day 36 sampling with 8 mice per group. The experiment shown in c was performed once with ﬁve mice per group.
*p < 0.0.5; ***p < 0.001; ****p < 0.0001; ns non-signiﬁcant (Kruskal–Wallis test with Dunn’s post hoc multiple comparison test). In b, c, the scale bar= 5
mm
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Fig. 6MLKL-mRNA combined with anti-PD1 inhibition improves protection. a Schematic representation of the experiment. B16-cells were s.c. inoculated in
the right and, on day 3, in the left ﬂank of C57BL/6J mice. On days 6 and 10, the tumor on the right ﬂank was injected with saline or 10 µg mRNA encoding
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when the tumor in the right ﬂank had reached a size of 1000mm3. *p < 0.0.5 (log-rank test of Kaplan–Meier curves). The experiment was performed once
with eight mice per group
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Fig. 7 Intratumor treatment with MLKL-mRNA induces antitumor T cell immunity. a Flow cytometric analysis of OT-I (top) and OT-II (bottom) proliferation
in response to a single intratumor treatment of B16-OVA tumors with saline or 10 µg mRNA encoding Fluc, tBid, or MLKL followed by electroporation
(n= 5). The results shown are representative for two independent experiments. ***p < 0.001; **p < 0,01; ns= not signiﬁcant (Kruskal–Wallis test with
Dunn’s post hoc multiple comparison test). b Induction of OVA MHC I (top) or OVA MHC II (bottom) speciﬁc T cell responses after intratumor treatment
of B16 tumors analyzed by IFN-γ ELISPOT. Representative ELISPOT pictures are shown above the graphs, which depict the number of spots from individual
mice. (n= 5). ***p < 0.001; **p < 0.01; *p < 0,05; ns= not signiﬁcant (Kruskal–Wallis test with Dunn’s post hoc multiple comparison test). c Flow
cytometric analysis of cytolytic activity as measured by an in vivo killing assay. The results shown are representative for three independent experiments.
**p < 0.001; ns= not signiﬁcant (Kruskal–Wallis test with Dunn’s post hoc multiple comparison test). d Kaplan–Meier plot showing the impact of CD4+ T
cell depletion and CD8+ T cell depletion on the antitumor effect of intratumor MLKL-mRNA treatment. *p < 0.05. e, f Induction of neo-epitope speciﬁc T
cell responses after intratumor treatment of B16 (e) or CT26 (f) tumors analyzed by IFN-γ ELISPOT. Representative ELISPOT pictures are shown on top of
the graphs, which depict the number of spots from individual mice. In a, b, c, e, f, horizontal lines indicate the mean and error bars the standard deviation.
*p < 0.05; **p < 0.01; ns= not signiﬁcant (Kruskal–Wallis test with Dunn’s post hoc multiple comparison test)
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patients. Recently, Kreiter et al. identiﬁed several immunogenic
neo-epitopes present in B16 and CT26 cells44. This enabled us to
address whether intratumor treatment with tBid- or MLKL-
mRNA could induce T cell responses directed against a subset of
these neo-epitopes. In the B16 model, we determined the T cell
response directed against the major histocompatibility complex
(MHC) class II-restricted neo-epitope B16-M30 or its wild-type
counterpart B16-WT30 by IFN-γ-speciﬁc ELISPOT. Notably, the
peptides corresponding to B16-M30 and -WT30 differ by a single
amino acid residue. Splenocytes of B16-bearing mice that had
been treated with MLKL-mRNA showed a pronounced reactivity
against the mutated B16-M30 neo-epitope but did not respond
against the B16-WT30 peptide (Fig. 7e). Neo-epitope-speciﬁc T
cell responses were also strongly induced in CT26 mice following
intratumor MLKL-mRNA administration, and, as in the B16
model, were undetectable after treatment with phosphate-
buffered saline (PBS), control or tBid-mRNA (Fig. 7f).
Migratory Batf3 DCs and type I IFN signaling control anti-
tumor T cells. Type I IFN-mediated activation of the Batf3-
dependent CD103+ DC subset is critically required for the
spontaneous induction of antitumor T cell responses and for the
therapeutic beneﬁt of intratumor treatment with Toll-like
receptor (TLR) and STING agonists and oncolytic viruses45–48.
To gain more insight into the immune pathways responsible for
the MLKL-mRNA-mediated antitumor responses, we probed the
inﬂux of DCs in the tumor bed and in the tumor draining lymph
node by ﬂow cytometry on days 1 and 2, respectively, after two
intratumor treatments with mRNA encoding MLKL (Fig. 8a, b;
Supplementary Fig. 6). Batf3-dependent DCs (conventional type
1 DCs or cDC1) and IRF4-dependent DCs (cDC2) represent the
two major classes of DCs and can be discriminated by their
distinct expression of XCR1 (cDC1) versus CD172α (cDC2).
Compared to mock treated mice, a strong inﬂux of cDC1 and
cDC2 DCs was apparent in the tumor bed and its draining lymph
nodes in mice that had been treated intratumorally with mRNA
coding for MLKL (Fig. 8a, b). To address the role of Batf3 DCs in
the induction of CD8+ T cell responses, we compared the cyto-
lytic activity between wild-type mice and Batf3-deﬁcient mice49.
In contrast to wild-type mice, B16-OVA-inoculated Batf3
knockout mice did not mount an OVA-speciﬁc cytotoxic T cell
response upon intratumor treatment with MLKL-mRNA, con-
ﬁrming the crucial involvement of the CD8α DC subset for T cell
priming (Fig. 8c). Furthermore, initial priming of CD8+ T cells
depended on the migration of DCs to the draining lymph nodes,
since mice that are deﬁcient in CCR7, the chemokine receptor
crucial for the migration of tissue DCs to lymph nodes, displayed
defective OT-I T cell proliferation upon intratumor treatment
with MLKL-mRNA of B16-OVA tumors (Fig. 8d). Finally, we
assessed the involvement of type I IFN signaling in the ther-
apeutic beneﬁt of intratumor MLKL-mRNA treatment with an
in vivo cytolytic activity assay in Ifnar1−/− mice. IFNAR1 deﬁ-
ciency totally abrogated the cytolytic activity in response to
intratumor MLKL-mRNA treatment, demonstrating the necessity
of type I IFN signaling (Fig. 8e).
MLKL-mRNA stalls tumor growth in humanized mice. In a
ﬁnal set of experiments, we exploited the potential of mRNA
coding for human MLKL (hMLKL) to induce an antitumor effect.
We ﬁrst evaluated the sensitivity of different human melanoma
cell lines and early passage human tumor cells to cell death
induced after transfection of mRNA encoding hMLKL. Flow
cytometric analyses of mRNA-transfected human melanoma cell
lines, early passage melanoma cells, and RL human B lymphoma
cells showed that, unlike mock transfection, Fluc-mRNA and
more extensively hMLKL-mRNA transfection resulted in cell
death (Fig. 9a).
To assess the therapeutic potential of intratumor hMLKL-
mRNA treatment of a human tumor in vivo, we used mice with a
humanized adaptive immune system. Irradiated newborn NOD-
SCID-gamma (NSG) mice that had received an intrahepatic
injection of human CD34+ stem cells, were inoculated s.c. with
2.5 × 106 human RL follicular lymphoma cells. At days 11 and 15,
when a palpable tumor could be observed, the tumors were
treated with saline or with mRNA encoding Fluc or hMLKL
(Fig. 9b). Intratumor administration of saline or mRNA encoding
Fluc resulted in comparable tumor growth. However, a striking
antitumor effect following intratumor treatment with hMLKL-
mRNA was observed, which signiﬁcantly delayed tumor growth
and increased the median survival time of the mice (Fig. 9b). In a
repeat experiment in this human tumor model, MLKL mRNA
outperformed tBid mRNA treatment in controlling tumor growth
(Supplementary Fig. 9 and Supplementary Table 1). These results
suggest that an hMLKL-mRNA-based antitumor treatment could
be beneﬁcial in a clinical setting.
Discussion
Stimuli that turn the immune-suppressive TME into a milieu that
is favorable for the activation of antitumor T cell responses can
induce potent antitumor immunity. In this study, we describe an
approach to elicit protective antitumor immunity based on the
intratumor administration of hypo-inﬂammatory mRNA that
encodes the necroptotic cell death executioner protein MLKL.
This approach elicited tumor antigen-speciﬁc CD4+ and CD8+ T
cell responses that stalled primary tumor growth and protected
against a rechallenge with the parental tumor cells. Strikingly,
MLKL-mRNA treatment of the tumors elicited strong T cell
responses directed against tumor neo-epitopes (Fig. 10).
Mechanistically, we found that Batf3-dependent DCs and type I
IFN signaling were vital to raise tumor-speciﬁc T cell responses
upon MLKL-mRNA treatment. It has been reported that che-
mically induced RIPK3 dimerization can trigger immunogenic
cell death and antitumor immunity by a process that requires NF-
κB-dependent cytokine expression and the production of
inﬂammatory cytokines by the dying tumor cells17. However, we
found no evidence that NF-κB was activated following MLKL
mRNA transfection. To address the question whether an intra-
tumor MLKL-mRNA treatment method holds promise for clin-
ical application, we performed experiments in mice with a grafted
human immune system that were subsequently inoculated with
HLA-matched human lymphoma-derived cancer cells. In these
mice, hMLKL-mRNA treatment strongly suppressed tumor
growth, suggesting that this approach could be effective in the
clinic.
Necroptosis can be induced by death receptor ligation, toll-like
receptor stimulation, or intracellular microbial nucleic acid sen-
sing, which precipitates on the activation of RIPK3 that in turn
phosphorylates MLKL. The phosphorylation of MLKL results in
its oligomerization and recruitment to the cell membrane where
the protein is thought to induce plasma membrane destabilization
by mechanisms that are still unclear. Some models favor direct
pore formation23,24 and others mention the requirement for the
recruitment of ion channels25. Recently, the ESCRT III
mechanism has been implicated in the regulation of the forma-
tion of MLKL-containing exosomes50–52. Prophylactic immuni-
zation of mice with cancer cells that are dying by necroptosis
induced by conditional activation of a RIPK3 transgene construct
can induce antitumor immunity17,18. Nonetheless, in situ
induction of necroptosis in tumors represents a major challenge,
as many tumor types display genetic and epigenetic alterations in
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Fig. 8 Lymphocyte inﬁltration and T cell activation depend on Batf3 DCs and type I IFN signaling. C57BL/6J or the indicated knockout mice (n= 5 per
group) were inoculated with B16-OVA cells and treated once (a, b) or twice (c–e) with mRNA encoding Fluc or MLKL. a One day after the ﬁrst treatment,
the tumor was dissected and the inﬂux of conventional type 1 (cDC1) and type 2 DCs (cDC2) was analyzed by ﬂow cytometry. **p < 0.01 (Mann–Whitney
U test). b Inﬂux of cDC1 and cDC2 cells in the tumor draining lymph node on day 2 after the ﬁrst treatment analyzed by ﬂow cytometry. **p < 0.01
(Mann–Whitney U test). c Three days after the second treatment of B16-OVA tumor carrying wild-type and Batf3−/− mice, OVA-labeled or irrelevant
peptide-pulsed naive CFSE-labeled splenocytes were injected i.v. into the mice and speciﬁc killing was determined 2 days later by ﬂow cytometry. d Prior to
Fluc- or MLKL-mRNA treatment of B16-OVA-bearing wild-type and CCR7−/− mice, CFSE-labeled OT-I T cells were adoptively transferred to these mice.
On day 14, 4 days after the second treatment, the tumor draining lymph nodes were isolated and OT-I cell proliferation was determined by ﬂow cytometry.
e Speciﬁc killing of OVA-labeled or irrelevant peptide-pulsed naive CFSE-labeled splenocytes injected i.v. 3 days after a second intratumor treatment of
B16-OVA-bearing wild-type and Ifnar1−/− mice with Fluc-mRNA or MLKL-mRNA. Representative ﬂow cytometric plots or histograms are shown in each
panel and the data points are shown as dot plots. In a–e, horizontal lines indicate the mean. Error bars depict the standard deviation
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the pathways leading to necroptosis. For this reason, we opted to
use mRNA encoding a downstream executioner of necroptosis,
i.e., MLKL. This strategy enabled us to induce necroptotic cell
death and subsequent antitumor immunity even in the context of
the RIPK3-deﬁcient CT26 tumor model. Therefore, loss of RIPK3
and MLKL expression as observed in many cancer cells would
likely not compromise the MLKL-mRNA approach described
here. The efﬁciency of the antitumor effect of the MLKL-mRNA
treatment correlates with the extent of necroptosis-like cell death
that is induced in the tumor cells and not with the extent of
induced cell death per se, since tBid-mRNA treatment, which
induced a comparable degree of cell death as MLKL-mRNA,
resulted in very poor antitumor activity. It is surprising that
transfected mRNA encoding wild-type MLKL could kill cells
because it has been reported that induced expression of wild-type
MLKL in mouse dermal ﬁbroblasts failed to do so22. We speculate
that the MLKL expression levels in mRNA-transfected cells
rapidly reach a critical concentration that could lead to the for-
mation of amyloid-like polymers that induce necroptosis40.
Intratumor MLKL-mRNA treatment induced T cell responses
against several neo-epitopes with known protective potential44. It
has also been reported that the induction of T cell responses
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Fig. 9 Intratumor MLKL-mRNA treatment reduces tumor growth in humanized mice. a Human melanoma cell lines (501 Mel, BLM, SK-Mel28), human
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(n= 9) followed by electroporation. Starting 8 days after tumor inoculation and during the treatments, 30 µg Flt3 ligand was given daily. Tumor growth was
measured over time. The animals were culled when the tumor had reached a size of 100mm2. ****p < 0.001 (log-rank test of Kaplan–Meier curves)
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directed against mutated tumor neo-epitopes is associated with
improved clinical outcome. As T cells that recognize these
mutated neo-epitopes have not been subjected to central toler-
ance induction, they are considered to be of superior quality as
compared to those recognizing non-mutated antigens53,54. Based
on these ﬁndings, active immunization strategies are being pur-
sued to evoke T cells recognizing an individual patient’s tumor
neo-epitopes55. A limitation of such a strategy is the critical
dependency on the reliability of the algorithms used to predict the
immunogenicity of mutated peptide sequences. In addition, neo-
epitopes are highly speciﬁc for a given tumor and patient, which
implies that for each patient a personalized new vector or delivery
system has to be generated to elicit neo-epitope-speciﬁc respon-
ses56,57. The MLKL-mRNA-based therapy described here resulted
in the clear induction of tumor antigen-speciﬁc CD4+ and CD8+
T cell responses without a necessity for tumor sequencing, epi-
tope prediction, and production of a personalized vaccine vector
(Fig. 6e, f). Therefore, we speculate that our approach could be
developed as an intervention to induce tumor antigen-speciﬁc T
cell responses early on in cancer patients. This could trigger a
protective adaptive immune response, buy time for subsequent
characterization of the tumor mutanome by exome sequencing
and bio-informatic prediction tools, and subsequently boost the
primed immune response induced by the MLKL-mRNA treat-
ment with, for example, a follow-up therapeutic vaccination
based on the identiﬁed neo-epitopes.
Mechanistically, we provide evidence that the antitumor T cell
responses induced by MLKL-mRNA treatment require Batf3-
dependent cDC1, DC migration, and type I IFN signaling
(Fig. 7c–e). Hence, MLKL-mRNA treatment may deploy the same
cells and signaling cascades that have been described to be vital
for spontaneous antitumor T cell immunity, for T cell-related
abscopal effects of radiotherapy58, and for the therapeutic beneﬁt
of intratumor injection of TLR agonists59, STING agonists60, and
oncolytic viruses61,62.
The successful therapeutic outcome in mice with a humanized
immune system upon hMLKL-mRNA-based anticancer treat-
ment described here is an important step toward clinical appli-
cation. Manufacturing and clinical translation of mRNA-based
drugs has been established in recent years by several compa-
nies55,63,64. Identifying clinically implementable ways of deliver-
ing MLKL-mRNA into tumors is an important hurdle to
overcome on the path from bench side to the clinic. Injection of
mRNA followed by electroporation as described in this study
might be primarily applicable to easily accessible tumors, such as
melanoma or head and neck tumors. It is important to note that
an increasing armory of delivery vehicles is being developed by
academic groups and companies to deliver mRNA directly to
tumors in vivo65, opening avenues to also treat visceral tumors
with MLKL-mRNA.
Methods
Cell lines and culture conditions. Cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% of fetal calf serum, 2 mM of L-glutamine,
0.4 mM of Na-pyruvate, non-essential amino acids, 100 U/ml of penicillin, and 0.1
mg/ml of streptomycin at 37 °C in a humidiﬁed atmosphere containing 5% CO2.
Murine tumor cells used were melanoma cell lines (B16, B16-OVA, B16-F10) and
colon carcinoma cells (CT-26). Human melanoma cell lines (501 Mel, BLM, SK-
mel28) and early passage cultures (M018017 and M000921) were kindly provided
by Dr. Geert Berx from Ghent University. RL and B16 cells were purchased from
the American Type Culture Collection (ATCC) and cultured in conditions speci-
ﬁed by the manufacturer. CT26 cells were provided by the laboratory of Professor
Patrizia Agostinis (KU-Leuven). No full authentication was performed on the cell
lines and all cell lines tested negative for mycoplasma contamination.
Production of in vitro transcribed mRNA. The coding information for Fluc,
mouse tBid, mouse MLKL, and human MLKL were cloned into the in-house
generated plasmid vector pIVTstab that contains a T7 promoter, 5’ and 3′
untranslated region of human β globulin, and a poly A60 tail. The mRNA
expression plasmids pIVTstab-GFP, pIVTstab-Luc, pIVTstab-tBid, and pIVTstab-
MLKL were propagated in Escherichia coli MC1061 cells (Stratagene, La Jolla, CA,
USA) and puriﬁed using endotoxin-free QIAGEN-tip500 columns (Qiagen,
Chatsworth, CA, USA). The MLKL and tBid encoding plasmids were linearized
with PstI (New England Biolabs, MA, USA), whereas the OVA, GFP, and Fluc
encoding plasmids were linearized with SpeI (New England Biolabs, MA, USA).
The linearized plasmids were puriﬁed using a PCR puriﬁcation kit (Roche, Upper
Bavaria, Germany). The mRNA was produced with the T7 mMessage Machine Kit
(Ambion, Austin, Tx, USA) according to the manufacturer’s instruction. 5-
Methylcytidine and pseudo-uridine (TriLink, San Diego, CA, USA) were used in
the transcription reactions instead of cytidine and uridine, respectively. The in vitro
transcribed mRNA was puriﬁed by lithium chloride precipitation and subsequently
simultaneously capped and 2′-O-methylated to synthesize Cap 1 RNA from
uncapped RNA using the ScriptCap m7G Capping System Kit together with the
ScriptCap 2′-O-methyltransferase Kit (Ambion, Austin, TX, USA) according to the
manufacturer’s instruction. The capped in vitro transcribed mRNA was puriﬁed by
lithium chloride precipitation.
In vitro transfection. Cells were plated 24 h before transfection in a 6- or 96-well
plate at 106 or 104 cells/well, respectively. One million B16 cells were transfected
with 1 µg of mRNA complexed with Lipofectamine® RNAiMAX (Life Technolo-
gies, Ghent; Belgium) diluted in OptiMem to obtain a total volume of 300 µl. The
transfection mix was added to the cells and cells were incubated at 37 °C, 5% of
CO2 during a time period depending on the experiment. Transfection efﬁciency
was evaluated by measuring uptake of Cy-5-labeled eGFP mRNA and the onset of
translation of the transfected mRNA by determining GFP ﬂuorescence at different
time points after transfection using a triple-laser (B-V-R) LSR-II (Becton Dick-
inson, San Jose, CA, USA) ﬂow cytometer. The ﬂow cytometric data were analyzed
with FlowJo (Treestar, OR).
Analysis of cell death and caspase activity. B16 cells (106 cells/well in 6-well
plate) were analyzed at different time points after transfection with saline or 1 µg of
mRNA encoding Fluc, tBid, or MLKL. The extent of membrane permeability was
Necroptotic
tumor cells
DC
Migration
CD4+ and CD8+ T cell response
against tumor (neo)antigens
CD8+ T cell
CD4+ T cell
Intratumoral MLKL mRNA injection
followed by electroporation
MLKL mRNA
Tumor Lymph node
Fig. 10 Proposed mechanism of intratumor MLKL-mRNA treatment. In vitro transcribed mRNA encoding MLKL is injected in an established tumor and the
tumor is subsequently electroporated. In this way, the MLKL-mRNA can enter cells in the tumor mass and its evokes cell death. Batf3 DCs are attracted to
the dying tumor cells and will take up tumor-speciﬁc antigen and subsequently crosspresent it in the draining lymph node to CD4+ and CD8+ T cells.
These primed CD4+ and CD8+ T cells can then mount a cellular response directed against tumor-speciﬁc (neo)antigens
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assessed by staining with Sytox Blue Nucleic Acid Stain (4000X dilution) (Mole-
cular Probes, S11348). The cells were analyzed on a triple-laser (B-V-R) LSR-II
(Becton Dickinson, San Jose, CA, USA). First single cells were selected based on
their forward scatter (FSC) and side scatter (SSC). Next dead cells were identiﬁed
based on SYTOX blue positivity (Supplementary Fig. 2: gating strategy). The ﬂow
cytometric data were analyzed with FlowJo (Treestar, OR).
To analyze caspase activity and cell death, a FLUOstar OMEGA (BM, Labtech)
assay was performed. Therefore, 5 × 103 cells were seeded in a transparent 96-well
plate and transfected with saline or 5 ng of mRNA encoding Fluc, tBid, or MLKL.
In all, 2 µM of SYTOX Green nucleic acid stain (Molecular Probes (S7020) and
33 mM of Ac-DEVD-AMC (Peptanova, 317-V) was added to the cells. Cell death
was measured based on SYTOX Green ﬂuorescence (excitation 485 nm, emission
520 nm) and set relative to the signal of 0.05% of Triton X-100-treated cells.
Caspase activity was measured by cleavage of Av-DEVD-AMC into ﬂuorescent 7-
amino-4-methylcoumarin (AMC) (excitation 355 nm, emission 460 nm). The
DEVDase activity is expressed as fold induction compared to the maximal
ﬂuorescence intensity value of cells treated with 10,000 U/ml tumor necrosis factor
(TNF; eBioscience) and 2 µM TAK inhibitor (Analyticon Discovery GmbH).
To analyze MLKL protein expression and caspase 3 cleavage, a western blot was
performed. B16 cells (106 cells/well in 6-well plate) were transfected with saline or
1 µg of mRNA encoding Fluc, tBid, or MLKL. Twenty four hours after transfection,
the lysates were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (10% acrylamide) and MLKL and caspase-3 were visualized by
western blotting with, respectively, anti-MLKL (1000× dilution) (Millipore, Cat.
No. MABC604) and anti-caspase 3 (1000× dilution) (Cell Signaling Technology,
Cat. No. 9662S) antibodies.
To analyze the possible induction of NF-κB upon cell death evoked by the
transfected mRNAs, a luciferase assay was performed. B16 cells were seeded at 5 ×
104 cells per well in 24-well plates 24 h before transfection. Cells were transfected
with 50 ng of a plasmid in which the coding sequence of luciferase is under the
control of the NF-κB promoter (pConluc) and 100 ng of a plasmid expressing
β-galactosidase (pB-act-B-galactosidase). Twenty four hours later, the B16 cells
were transfected with saline or 100 ng of mRNA encoding GFP, tBid, or MLKL, or
as a positive control, the B16 cells were transfected with 25 ng TRAF6 expression
plasmid (pcDNA3.1-HA-TRAF6) or stimulated with 100 U/ml TNF. At different
time points, cells were lysed with luciferase lysis buffer (25 mM Tris-phosphate,
2 mM dithiothreitol, 2 mM CDTA, 10% glycerol, and 1% Triton X-100). Luciferase
activity was measured with a GloMax® 96 Microplate Luminometer (Promega) by
adding luciferin to the lysates. To normalize the luciferase activity, the
B-galactosidase activity was measured on a iMark microplate reader (Biorad). The
ratio of the β-galactosidase and luciferase activities was determined to normalize
for transfection efﬁciency.
To investigate whether the induced cell death requires transcription, a ﬂow
cytometric experiment was performed. B16 cells (106 cells/well in 6-well plate) were
transfected with 1 µg of the GFP-expressing plasmid pMAX-GFP combined with
saline or 1 µg of mRNA encoding Fluc, tBid, or MLKL. Half of the transfected cells
were treated with actinomycin D (1 µg/ml) immediately after transfection. Twenty
four hours after transfection, the extent of membrane permeability was assessed by
staining with Sytox Blue Nucleic Acid Stain (4000× dilution) (Molecular Probes,
S11348). The cells were analyzed on a triple-laser (B-V-R) LSR-II (Becton
Dickinson, San Jose, CA, USA). First single cells were selected based on their FSC
and SSC. Next dead cells and GFP-expressing cells were identiﬁed based on
SYTOX blue positivity (Supplementary Fig. 2: gating strategy) or GFP positivity.
The ﬂow cytometric data were analyzed with FlowJo (Treestar Inc., USA).
Live cell imaging. B16 cells were seeded at 15 × 103 cells per well in an 8-well
chamber (iBidi) in 200 µl of complete growth medium. Twenty four hours later,
cells were transfected with saline or 1 µg of mRNA encoding Fluc, tBid, or MLKL
just before imaging. Live cell imaging was performed on a Leica Sp5 AOBS confocal
microscope (Leica), using an ×40 HCX PL Apo UV 1.25 na oil objective. Images
were acquired in a sequential mode every 30 min.
Mice. Female C57BL/6 mice were purchased from Charles River France and female
BALB/cAnNCrl mice from Charles River Italy (via France). OT-I mice carrying a
transgenic CD8+ T cell receptor speciﬁc for the MHC-I-restricted OVA peptide
(257-264), OT-II mice carrying a transgenic CD4+ T cell receptor speciﬁc for the
MHC-II-restricted OVA peptide (323–339), CCR-7-, batf3-, and IFNAR1-deﬁcient
mice were bred at the breeding facility of the VIB-UGent Center for Inﬂammation
Research (VIB, Ghent, Belgium). NSG mice were bred at the breeding facility of the
University Hospital Ghent (UZ Ghent, Belgium). All mice were aged 7–10 weeks at
the start of the experiment. Animals were housed under speciﬁc pathogen-free
conditions in individually ventilated cages in a controlled 12-h day–night cycle and
given food and water ad libitum. All procedures involving animals were approved
by the local Ghent University ethics committee (accreditation nr. LA1400536,
Belgium), in accordance with European guidelines. Mice experiments are covered
under the following EC applications: EC2016-010 and ECD17/11. The mice were
allocated randomly to a group. The investigators were not blinded during data
collection or analysis.
In vivo bioluminescence imaging. For in vivo imaging, mice were inoculated s.c.
with 5 × 105 B16 cells. Six days after inoculation 10 µg of mRNA coding for Fluc
was injected into the tumor. To monitor Fluc activity, 150 mg/kg of D-luciferin
(PerkinElmer, Waltham, MA, USA) in PBS was injected i.v. at different time points
after Fluc mRNA injection. The mice were sedated and monitored using an IVIS
lumina II imaging system. Photon ﬂux was quantiﬁed using the Living Image
4.4 software (all from Caliper Life Sciences, Hopkinton, MA, USA).
In vivo mRNA electroporation. C57BL/6 mice and BALB/cAnNCrl mice that had
been inoculated s.c. with tumor cells were shaved at the site of tumor growth. A
total of 10 µg of mRNA dissolved in 10 µl of Hank’s Balanced Salt Solution (HBSS;
Gibco) was injected into the tumor using a U-100 insulin needle (BD Biosciences,
San Diego, CA, USA). Next a conductive gel (EKO-GEL, ultrasound transmission
gel, Egna, Italy) was applied at the tumor site to ensure electrical contact of the
electrodes with the skin and electroporation was performed. Two pulses of 20 ms
and 120 V/cm were delivered through spaced plate electrodes by an ECM® 830
Electroporation System (BTX ® Harvard apparatus). Mice were treated this way on
days 6 and 10 after tumor cell inoculation.
Tumor implantation and tumor growth measurement. In total, 5 × 105 B16
(OVA) cells or CT26 cells suspended in 100 μl of HBSS were injected s.c. into the
right ﬂank of each C57BL/6 or BALB/cAnNCrl mice, respectively. At days 6 and 10
after inoculation of the tumor cells, mRNA was injected into the tumor and the
tumor was subsequently electroporated. For the comparison of the mRNA treat-
ment with an antracyline treatment, B16 inoculated mice received dox (3 mg/kg) at
days 6, 8, and 10 or during 3 weeks every 2 days. Unless otherwise indicated, these
dox doses were injected perilesionally, s.c. next to the tumor border. For the
combination therapy, 200 µg of anti-PD1 from BioXcell (Cat. No. BE0146) or an
isotype control antibody from BioXcell (Cat. No. BE0089) was injected intraper-
itoneally during 3 weeks every 3 days, starting on day 6 after inoculation of the ﬁrst
tumor. Depending on the set-up of the experiment, the primary tumor was
removed and 5 × 105 B16 or CT26 cells diluted in 100 μl of HBSS were injected s.c.
into the left ﬂank of each C57BL/6 or BALB/cAnNCrl mice, respectively, or 2 × 105
B16F10 or CT26 cells were injected i.v. The tumor size was measured every 2 days
with an electronic digital caliper. The tumor volume was calculated as the length ×
width × height (in mm3). The mice were humanely euthanized when the volume of
the tumor reached 1000 mm3. For the experimental lung colonization assay
experiments, mice were euthanized 12 days after i.v. injection of the tumor cells
and tumor nodules were counted. In the CT26 model, lung tumor burden was
quantiﬁed after tracheal ink (1:10 diluted in PBS) injection and ﬁxation with
Fekete’s solution (5 ml 70% ethanol, 0.5 ml formalin, and 0.25 ml glacial acetic
acid).
Analysis of DC inﬁltration in the tumor draining lymph nodes. B16 cells (5 ×
105) diluted in 100 μl of HBSS were injected s.c. into the right ﬂank of each C57BL/
6 mouse. At day 6 and 10 after inoculation of the tumor cells, mRNA was injected
into the tumor and the tumor was subsequently electroporated. Two days after the
second treatment, the draining lymph nodes were dissected and passed through
70 µm nylon strainers (BD Biosciences, San Diego, CA, USA) to obtain single-cell
suspensions. Cells were stained with anti-CD16/CD32 (500× dilution) (BD Bios-
ciences) to block Fc receptors followed by staining with Fixable Viability Dye eﬂuor
780 (1000× dilution) (eBioscience), Ly6C-FITC (400× dilution) (BD Biosciences),
XCR1-BV510 (300× dilution) (Biolegend), CD172α-PerCP-eﬂuor710 (200× dilu-
tion) (eBioscience), CD64-biotin BV786 SA (300× dilution) (Biolegend), CD207-
AF647 (200× dilution) (eBioscience), CD11c-PE-eﬂuor610 (800× dilution)
(eBioscience), MHCII-AF700 (800× dilution) (eBioscience), CD3-PE-Cy5 (200×
dilution) (eBioscience), and CD19-PE-Cy5 (400× dilution) (eBioscience). Cell
analysis was performed on a ﬁve-laser fortessa (Becton Dickinson, San Jose, CA,
USA), and data were analyzed using the FlowJo software (Treestar, OR). First, live
single cells were identiﬁed based on SSC, FSC, and live/dead stain. T and B cells
were gated out based on their CD3 and CD19 positivity, respectively. Subsequently,
monocyte-derived DCs were identiﬁed as CD64+MHCII+ cells, cDC1 as CD64−
MHCII+ CD11c+ XCR1+, and cDC2 as CD64−MHCII+ CD11c+ CD127α+ cells.
See Supplementary Fig. 6 for gating strategy.
In vivo T cell proliferation assay. Two days prior to mRNA immunization, 2 ×
106 OT-I or OT-II cells were puriﬁed and labeled with 5 µM of CFSE (Invitrogen,
Merelbeke, Belgium) and subsequently adoptively transferred via i.v. injection into
mice that had been s.c. inoculated with B16 cells. Four days after the mRNA
treatment, draining lymph nodes were isolated and OT-I or OT-II cell division was
analyzed by ﬂow cytometry. Cells were stained with anti-CD16/CD32 (500×
dilution) (BD Biosciences) to block Fc receptors followed by staining with Fixable
Viability Dye (1000× dilution) (BD Biosciences), CD8 PE-Cy7 (200× dilution)
(eBiosciences), CD3 eﬂuor450 (200× dilution) (eBioscience), anti-CD19 allophy-
cocyanin (APC; 200× dilution) (BD Biosciences), and MHC-I dextramer H-2 Kb/
SINFEKL-PE (500× dilution) (Immundex). The experiments were performed on a
triple-laser (B-V-R) LSR-II (Becton Dickinson, San Jose, CA, USA), and data were
analyzed using the FlowJo software (Treestar, OR). Single cells were gated based on
FSC and SSC. Living cells were selected and T cells gated for CD3+ CD19− T cells.
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Within the CD8+ T cells or CD4+ T cells, OVA-speciﬁcity was gated by labeling
with MHC-I SINFEKL-PE dextramer. See Supplementary Fig. 4 for the gating
strategy.
In vivo killing assay. Splenocytes from female mice were pulsed with 1 µg/ml of
the MHC-I-restricted OVA257-264 peptide or HIV-1 gag peptide as a control before
labeling with 5 or 0.5 µM of CFSE (Invitrogen, Merelbeke, Belgium), respectively.
Labeled cells were mixed at a 1:1 ratio and a total of 1.5 × 107 mixed cells were
adoptively transferred into immunized mice 3 days after the second mRNA
treatment. Forty eight hours later, splenocytes from mice were isolated and passed
through 70 µm nylon strainers (BD Biosciences, San Diego, CA, USA) to obtain
single-cell suspensions. Red blood cells were lysed using ACK red blood cell lysis
buffer (BioWhittaker, Wakersville, MD, USA). Next, splenocytes were analyzed by
ﬂow cytometry. Percentage of antigen-speciﬁc killing was determined using the
following formula: (1− (%CFSEhi cells/%CFSElow cells)treated mice/(%CFSEhi cells/
% CSFElow cells)non-treated mice) × 100. The experiments were performed on a triple-
laser (B-V-R) LSR-II (Becton Dickinson, San Jose, CA, USA) and analyzed using
the FlowJo software (Treestar, OR). Single cells were gated based on their SSC and
FSC. Next CFSE-positive cells were selected. See Supplementary Fig. 5 for gating
strategy.
ELISPOT analysis. C57BL/6 mice were inoculated with 5 × 105 B16 cells, and at
days 6 and 10, the mice were treated with saline or 10 µg mRNA encoding Fluc,
tBid, or MLKL. Two days after the second treatment, spleens were isolated and
passed through 70 µm nylon strainers (BD Biosciences, San Diego, CA, USA) to
obtain single-cell suspensions. Red blood cells were lysed using ACK red blood cell
lysis buffer (BioWhittaker, Wakersville, MD, USA) and 2.5 × 105 cells were cul-
tured for 24 h in wells of anti-IFN-γ (Diaclone, Besancon, France) pre-coated 96-
well plates in the presence of 10 µg/ml peptide. The following synthetic, high-
performance liquid chromatography-puriﬁed peptides were used for restimulation:
OVA 257–264 (SIINFEKL), OVA 323–339 (SQAVHAAHAEINEAGR), CT26-
M20 (PLLPFYPPDEALEIGLELNSSALPPTE), CT26-M26 (VILPQAPSGPSYA-
TYLQPAQAQMLTPP), CT26-M03 (DKPLRRNNSYTSYIMAICGMPLDSFRA),
CT26-M37 (EVIQTSKYYMRDVIAIESAWLLELAPH), CT26-M27 (EHIH-
RAGGLFVADAIQVGFGRIGKHFW), B16-M30 mut (PSKPSFQEFVDWENV-
SPELNSTDQPFL), and B16-M30 WT (PSKPSFQEFVDWEKVSPELNSTDQPFL).
CD8+ and CD4+ depletion experiments. In total, 5 × 105 B16 cells diluted in
100 μl of HBSS were injected s.c. into the right ﬂank of each C57BL/6 mouse. At
days 6 and 10 after inoculation of the tumor cells, mRNA was injected into the
tumor and the tumor was subsequently electroporated. In the CD8+ depletion
assay, 200 µg of anti-mouse CD8α antibody (clone YTS 169.4, BioXCell) was i.p.
injected on days 5 and 10 after tumor inoculation. In the CD4+ depletion assay,
200 µg of anti-mouse CD4 antibody (clone GK1.5, BioXCell) was i.p. injected at
days 3, 6, and 9 after tumor inoculation. The tumor size was measured every 2 days
with an electronic digital caliper as described above.
Mice with a humanized immune system. To obtain hematopoietic stem cells
(HSC) that HLA type matched with the human RL tumor cells used for the
antitumor experiment, cord blood cells were stained with HLA-A2-FITC (BD
Pharmingen) or with HLA-ABC-PE (BD Pharmingen) as a positive control prior to
HSC isolation. Samples were acquired on an Attune Nxt Acoustic Focusing Cyt-
ometer (Life Technologies). HLA.A2+ samples were selected for CD34+ stem cells.
To that end, viable mononuclear cells were isolated by gradient separation to
isolate the viable mononuclear cells. Next, CD34+ cells were isolated using a direct
CD34+ progenitor cell isolation kit (Miltenyi). To evaluate the purity of the iso-
lated stem cells, a ﬂow cytometric staining was performed (human CD3-PE (BD
Pharmingen)/human-CD34-APC (BD Pharmingen)). Samples were acquired on an
Attune Nxt Acoustic Focusing Cytometer (Life Technologies). The purity of the
injected cells reached 92–98%. To generate mice with a humanized immune sys-
tem, newborn NSG mice (2 days old) received a sublethal irradiation of 100 cGy
followed by an intrahepatic delivery of CD34+ stem cells. Eight and 12 weeks after
CD34+ stem cell transfer, peripheral blood was analyzed for the presence of both
human and mouse CD45+ cells to analyze engraftment (Supplementary Fig. 7 and
8). Samples were acquired on an LSR ﬂow cytometer (BD) and analyzed by FACS
Diva software (BD). The mice were s.c. inoculated with 2.5 × 106 human RL fol-
licular lymphoma cells at 13 weeks after stem cell transfer. From day 8 onwards, the
mice received a daily intraperitoneal injection of 30 µg of recombinant human
FLT3-L protein. On days 11 and 15 after the RL cell injection, the tumors were
injected with saline or with 10 µg of mRNA encoding Fluc, human tBid, or MLKL
followed by electroporation. Tumor growth was measured over time. The animals
were euthanized when the tumor had reached a size of 100 mm2.
Hematologic analysis. On days 11, 18, and 25, blood was collected from the tail
vein in EDTA-coated microvette tubes (Sarstedt) and analyzed in a Hemavet 950FS
(Drew Scientiﬁc) whole blood counter.
Statistical analyses and data presentation. Statistical analyses were performed
using the GraphPad Prism 7 software. Cox regression analyses showed that there
was no difference between the three repeats of Figs. 2b and 3b. Statistical sig-
niﬁcance between survival rates was done by comparing Kaplan–Meier curves
using log-rank test. Statistical signiﬁcance between experimental groups was
assessed using Kruskal–Wallis test (with Dunn’s post hoc multiple comparison test,
as stated). Non-parametric or group comparisons with small sample sizes were
assessed by unpaired two-tailed Mann–Whitney U test.
Data availability. All data supporting the ﬁndings of this study are available within
the article or from the corresponding author upon request.
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